Get $5 off $25+ with SAVE5

FIND A STORE NEAR YOU

Clinical white paper

PMS Relief Capsule: formulation and evidence review

This page is a condensed, citation-preserving summary; the linked PDF is the complete document.

By Matt Crane, PhD, Co-Founder & Chief Science Officer · Last reviewed July 2026

PDF · 4 pages Read the full white paper (PDF) Open the complete formulation and evidence review

Executive summary

This page is a condensed, citation-preserving summary of the full white paper; the linked PDF is the complete document.

We designed PMS Relief Capsule for cyclical use around menstruation, combining magnesium and vitamin D with plant compounds selected for normal inflammatory, antioxidant, mast-cell, and nervous-system pathways.[5][7][8] Our registered open-label crossover study adds finished-formula observations but cannot establish a placebo-controlled effect.

Formulation rationale

A cyclical, multi-pathway formula

We use a cyclical regimen because menstrual discomfort has a defined time course and inflammatory mediators change around menstruation.[5][15] We included magnesium and vitamin D because human studies evaluated nutrient status and supplementation in menstrual symptoms.[9][10][11] We mapped the remaining botanicals across normal prostaglandin, leukotriene, oxidative, mast-cell, and stress-response pathways, while recognizing that mechanistic evidence is not finished-formula proof.[13][16][17]

Formula at a glance

IngredientForm / amountRole in the formula
Magnesium Sucrosomial magnesium; use current Supplement Facts for amount Normal muscle, nerve, and cycle function
Vitamin D3 Cholecalciferol; use current Supplement Facts for amount Nutrient pathway studied in menstrual discomfort
Curcumin Standardized turmeric extract Normal inflammatory and antioxidant support
Quercetin Plant flavonoid Antioxidant and mast-cell pathway support
Resveratrol Plant polyphenol Antioxidant pathway support
Silymarin Milk thistle flavonolignans Endogenous antioxidant-system support
Green tea catechins Standardized extract Polyphenol support
Ashwagandha Root extract Normal stress-response support
Boswellia Standardized resin extract Normal inflammatory-response support

See current product facts

Published literature

The evidence we used

Our 21-source review includes measurement research, nutrient interventions, mechanistic reviews, and observational studies; each evidence type answers a different question.[1][11][21][1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22]

  • Measurement and timingFoundational and clinical reviews

    Validated symptom measurement and menstrual-discomfort biology define what to measure and when.[1][5]

  • Magnesium and vitamin DHuman evidence

    Studies evaluated oral magnesium, vitamin D status, and vitamin D supplementation in deficient participants.[9][10][11]

  • Inflammatory pathwaysMechanistic and clinical context

    Prostaglandin and leukotriene literature supports a multi-pathway research rationale.[15][16]

  • Mast-cell biologyTranslational reviews

    Reviews describe emerging mast-cell biology; they do not show that this product changes a disease outcome.[17][18][19][20]

Finished-formula evidence

Our open-label crossover study

In our third-party open-label crossover study, 48 participants recorded a baseline menstrual cycle, began the formula on day four of menstruation according to the source protocol, and used their subsequent cycle as the within-person comparison.[22] Participants reported significant reductions at p<0.01 in every surveyed symptom, including cramping, digestive upset, mood swings, and bloating.[22] hs-CRP moved in the hypothesized direction but did not meet the study's significance threshold, so we do not present it as an efficacy result.[22] Without blinding or placebo control, reported changes do not establish causation.[22]

Funding disclosure: The study was independently conducted by Citrus Labs and funded by Semaine.

See the full study design, results, and limitations

Full references

  1. Chesney MA, Tasto DL. Development of the menstrual symptom questionnaire. Behav Res Ther. 1975;13:237-244.Measurement
  2. Oladosu FA, et al. Nonsteroidal antiinflammatory drug resistance in dysmenorrhea. Am J Obstet Gynecol. 2018;218:390-400.Review
  3. Stosic R, et al. Responsible self-medication and OTC analgesic use. Int J Pharm Pract. 2011;19:236-245.Survey
  4. Kantor ED, et al. Trends in dietary supplement use among US adults. JAMA. 2016;316:1464-1474.Epidemiology
  5. Harel Z. Dysmenorrhea in adolescents and young adults. J Pediatr Adolesc Gynecol. 2006;19:363-371.Clinical review
  6. Chocano-Bedoya PO, et al. Mineral intake and premenstrual syndrome risk. Am J Epidemiol. 2013;177:1118-1127.Cohort study
  7. Attiq A, et al. Natural products and inflammatory pathways. Front Pharmacol. 2018;9:976.Review
  8. Maroon JC, et al. Natural anti-inflammatory agents. Surg Neurol Int. 2010;1:80.Review
  9. Facchinetti F, et al. Oral magnesium and premenstrual mood changes. Obstet Gynecol. 1991;78:177-181.Human clinical
  10. Abdul-Razzak KK, et al. Vitamin D and PTH status in severe dysmenorrhea. J Pediatr Adolesc Gynecol. 2014;27:78-82.Observational
  11. Moini A, et al. Vitamin D in primary dysmenorrhea with vitamin D deficiency. Gynecol Endocrinol. 2016;32:502-505.Randomized trial
  12. Olafsdottir LB, et al. Irritable bowel syndrome and dysmenorrhea: 10-year follow-up. Gastroenterol Res Pract. 2012;2012:534204.Cohort study
  13. Augoulea A, et al. Endometriosis, inflammation, and oxidative stress. Arch Gynecol Obstet. 2012;286:99-103.Review
  14. Lousse JC, et al. Peritoneal endometriosis and inflammatory biology. Front Biosci. 2012;4:23-40.Review
  15. Strömberg P, et al. Vasopressin and prostaglandins in premenstrual pain and dysmenorrhea. Acta Obstet Gynecol Scand. 1984;63:533-538.Human study
  16. Abu JI, Konje JC. Leukotrienes in gynecology. Hum Reprod Update. 2000;6:200-205.Review
  17. Zhang L, et al. Mast cells and irritable bowel syndrome. J Neurogastroenterol Motil. 2016;22:181-192.Review
  18. Kirchhoff D, et al. Mast cells in endometriosis. Expert Opin Ther Targets. 2012;16:237-241.Review
  19. Hart DA. Mast cells in multiple sclerosis and endometriosis. Int J Inflam. 2015;2015:452095.Review
  20. Binda MM, et al. Targeting mast cells in endometriosis. Expert Opin Ther Targets. 2017;21:67-75.Review
  21. Bertone-Johnson ER, et al. Inflammation markers and menstrual symptom severity. Hum Reprod. 2014;29:1987-1994.Observational
  22. Semaine Health. PMS Relief Capsule white paper, v7. Observational open-label crossover study and results.Finished-formula observational
Read the full white paper (PDF)View the clinical evidenceSee current product facts

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Your Cart
Taxes and shipping calculated at checkout